-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Influenza-virus-IN-3
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2412451-16-0.gif)
| Category | Influenza Virus |
| CAS | 2412451-16-0 |
| Description | Influenza virus-IN-3 (compound 9) is a potent and selective influenza virus inhibitor with IC50s of 0.88, 0.10, 5.5, 0.51 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-3 shows antiviral and NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-3 shows low cytotoxicity with an CC50 of >200 µM. |
Product Information
| Synonyms | Influenza virus-IN-3|CHEMBL4788913|HY-146000|CS-0459577 |
| Molecular Weight | 456.6 |
| Molecular Formula | C25H32N2O4S |
| Canonical SMILES | CCC(CC)OC1C=C(CC(C1NC(=O)C)NCC2=CC=C(C=C2)C3=CSC=C3)C(=O)O |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 658 |
| Exact Mass | 456.20827868 |
| In Vitro | The IC50s of influenza virus-IN-3 (compound 9a) against H5N1, H5N2, H5N6, H5N8, H5N1eH274Y, N1 (H1N1pdm09) and N2 (H3N2) were 118.17, 1442.6, 34543.33, 78.06, 10206, 0.00048, 0.01222 nM, respectively, showing NA (neuraminidase) inhibitory activity. |
| Target | IC50: 0.88 µM (H5N1); 0.10 µM (H5N2); 5.5 µM (H5N6); 0.51 µM (H5N8) |
| XLogP3-AA | 1.4 |
